Licochalcones have extensive anti-tumor bioactivity, involving regulation of multiple oncogenic pathways (e.g., EGFR/ERK, PI3K/AKT/mTOR, p38/JNK, JAK2/STAT3) and perturbation of cancerous phenotypes (proliferation, apoptosis, autophagy, and so on).[220] Licochalcone A induces ferroptosis in liver cancer cells through downregulating the SLC7A11/GPX4 axis;[221] it is also identified as a PRMT6 inhibitor for breast cancer treatment in preclinical research.[222] However, the potential property of licochalcones to induce ferroptosis and reshape TME in a PRMT-dependent manner is poorly understood. Here, AKT1 is linked to breast carcinoma.